Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

BridgeBio Pharma (BBIO) trades at $69.71, up 0.48% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth reaching $502M in 2025, but continues to report significant net losses (-$725M) and negative cash flow from operations. Recent positive developments include FDA acceptance and priority review for BBP-418 for LGMD2I/R9 with a PDUFA date of November 27, 2026, and upcoming Phase 3 trial presentations for multiple pipeline assets.
The investment case hinges on pipeline execution and commercialization success. While analyst consensus is strongly bullish with a $102.75 price target, substantial risks include persistent cash burn, high debt ($1.72B), negative shareholder equity (-$1.47B), and reliance on financing activities to fund operations. Near-term catalysts include regulatory decisions and clinical trial readouts across multiple genetic disease programs.
Read full analysis

Key Stats

  • Market Cap
    $13.78B
  • Sector
    Health
  • 3M Drawdown
    -18.03%
  • Enterprise Value
    $15.33B
  • Dividend Yield
    -
  • Typical Hold Time
    60 days
$70.24
52W Low: $42.78
01 Jul 2025
52W High: $79.91
22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $13.78B, with an enterprise value of $15.33B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $42.78 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -18.03%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 60 days, indicating typical investor behavior on the platform.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.


People also bought


Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Key Stats

  • Market Cap
    $13.78B
  • Sector
    Health
  • 3M Drawdown
    -18.03%
  • Enterprise Value
    $15.33B
  • Dividend Yield
    -
  • Typical Hold Time
    60 days
$70.24
52W Low: $42.78
01 Jul 2025
52W High: $79.91
22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $13.78B, with an enterprise value of $15.33B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $42.78 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -18.03%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 60 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!